APA (7th ed.) Citation

Tepper, S. J., Cady, R. K., Silberstein, S., Messina, J., Mahmoud, R. A., Djupesland, P. G., . . . Siffert, J. (2015). AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache, 55(5), 621-635. https://doi.org/10.1111/head.12583

Chicago Style (17th ed.) Citation

Tepper, Stewart J., Roger K. Cady, Stephen Silberstein, John Messina, Ramy A. Mahmoud, Per G. Djupesland, Paul Shin, and Joao Siffert. "AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder Vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks." Headache 55, no. 5 (2015): 621-635. https://doi.org/10.1111/head.12583.

MLA (9th ed.) Citation

Tepper, Stewart J., et al. "AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder Vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks." Headache, vol. 55, no. 5, 2015, pp. 621-635, https://doi.org/10.1111/head.12583.